Skip to main content
Industry News
FDA OKs sNDA for bupivacaine liposome injectable

The FDA approved Pacira BioSciences' supplemental new drug application to expand the indication of Exparel, its injectable bupivacaine liposome suspension treatment to cover pediatric patients aged 6 years and older. The drug is used for post-surgical non-opioid pain control.

Full Story: